Affecting approximately 1 in 40 adults, Gouty arthritis is characterized by severe swelling and attacks of pain, tenderness, redness, warmth and swelling in the joints that result from abnormal metabolism of uric acid in the tissues and blood. Usually, the joint at the base of the big toe gets affected due to redness, stiffness, swelling and burning pain. High blood pressure, high cholesterol, diabetes and heart disease may increase of gouty arthritis.
Affecting mostly men between the ages of 30 to 60 years, Gouty arthritis is primarily caused by the accumulation of too much uric acid in the joints that causes nodules under the skin, known as tophi. Increased levels of uric acid in the blood results from chronic kidney disease, obesity and certain medications (diuretics). One is more likely to have gouty arthritis if there is a family history about it while obese people are at a higher risk for gout.
Sometimes, consumption of high-protein food, sudden changes in diet and weight gain or loss may also produce excessive amount of uric acid. One of the most painful forms of arthritis, Gouty arthritis is typically more common in men than in women and future damage to joints can be avoided by treatment.
Get a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14993
Various symptoms associated with gouty arthritis are as follows:
-Sudden onset of pain
-Swelling and redness
-Tenderness in the joint
-Limited movement in the affected joint
-Itching in the skin
Based on geography, the gouty arthritis market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Out of these regions, North America holds a leading position in the gouty arthritis market followed by Europe. The prime factors which are driving the growth of the market in these regions are increasing awareness amongst the patient population, consumption of high-protein food and certain sedentary habits such as smoking tobacco and drinking.
Furthermore, increasing disposable income of the population is also propelling the growth of gouty arthritis market. Asia Pacific is the most promising region for the growth of gouty arthritis market as it is one of the emerging economies. The factors which would accentuate the growth of the market in Asia Pacific are increasing prevalence of obesity and certain genetic disorders, and development of therapeutic treatment as well as testing tools for the treatment of gouty arthritis. Moreover, huge population base in developing countries such as China, India and Brazil would also fuel the growth of gouty arthritis market in the coming years.
Some of the top players operating in the development of gouty arthritis therapeutics market are AstraZeneca PLC, Novartis AG, Polaris Group, BioCryst Pharmaceuticals, Inc., Teijin Pharma Limited, Nippon Chemiphar Co., Ltd., JW Pharmaceutical Corporation, Addex Therapeutics, LG Life Sciences, Ltd. and others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.Editor's Details
Last updated on: 07/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.